Insider Selling: Dyne Therapeutics (NASDAQ:DYN) CEO Sells $106,823.04 in Stock

Dyne Therapeutics, Inc. (NASDAQ:DYN) CEO John Cox sold 5,658 shares of Dyne Therapeutics stock in a transaction on Tuesday, September 8th. The shares were sold at an average price of $18.88, for a total value of $106,823.04. Following the completion of the transaction, the chief executive officer owned 357,507 shares in the company, valued at $6,749,732.16. This represents a 1.56% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Dyne Therapeutics Trading Down 4.0%

DYN opened at $18.42 on Friday. The company has a current ratio of 12.02, a quick ratio of 12.02 and a debt-to-equity ratio of 0.28. The firm has a market cap of $3.44 billion, a price-to-earnings ratio of -5.53 and a beta of 1.08. Dyne Therapeutics, Inc. has a 12 month low of $11.92 and a 12 month high of $27.31. The stock has a fifty day moving average price of $24.68 and a 200-day moving average price of $20.54.

Dyne Therapeutics (NASDAQ:DYN) last issued its quarterly earnings data on Thursday, July 30th. The company reported ($1.08) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.33). As a group, equities research analysts anticipate that Dyne Therapeutics, Inc. will post -3.51 earnings per share for the current fiscal year.

Institutional Trading of Dyne Therapeutics

Several large investors have recently bought and sold shares of the stock. Hilton Head Capital Partners LLC acquired a new stake in shares of Dyne Therapeutics during the first quarter worth $26,000. Strs Ohio acquired a new position in shares of Dyne Therapeutics in the 4th quarter valued at $51,000. Allworth Financial LP acquired a new position in shares of Dyne Therapeutics in the 2nd quarter valued at $62,000. Aster Capital Management DIFC Ltd purchased a new position in Dyne Therapeutics in the 4th quarter worth $84,000. Finally, Steward Partners Investment Advisory LLC raised its stake in Dyne Therapeutics by 102.1% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 4,880 shares of the company’s stock worth $95,000 after acquiring an additional 2,465 shares during the last quarter. Hedge funds and other institutional investors own 96.68% of the company’s stock.

Dyne Therapeutics News Summary

Here are the key news stories impacting Dyne Therapeutics this week:

• Positive Sentiment: Morgan Stanley reaffirmed its Buy rating on Dyne, signaling continued confidence in the company’s pipeline and long-term outlook. Morgan Stanley reaffirmed Buy rating
• Positive Sentiment: RBC maintained an Outperform rating, saying Dyne’s DM1 approach remains differentiated, although it reduced its price target from $35 to $30. Investors are also awaiting additional six- and 12-month data for DYNE-101 and topline results from the fully enrolled ACHIEVE expansion cohort, expected in the first quarter of 2027. RBC assessment of Dyne’s DM1 approach
• Neutral Sentiment: Unusually heavy call-option activity was reported, with roughly 20,532 calls traded versus average daily volume of about 464. The activity may indicate speculative expectations for a rebound or clinical-data catalyst, but it does not establish improving fundamentals. Unusually large options trading in DYN
• Neutral Sentiment: Reported short interest was zero shares, implying no meaningful short-selling position or days-to-cover exposure based on the figures provided. This is unlikely to be a major near-term trading catalyst.
• Negative Sentiment: JPMorgan downgraded DYN from Neutral to Underweight and cut its price target from $17 to $10. The move followed a rival DM1 therapy’s Phase 3 failure, which raised concerns about clinical and commercial risks across the disease class. JPMorgan downgrade following Novartis setback
• Negative Sentiment: An insider sold 900 shares for approximately $21,915, reportedly to cover tax withholding tied to vested equity awards. The sale was small relative to the insider’s remaining holdings, limiting its fundamental significance, but it may add modestly to cautious sentiment. Dyne insider stock sale

Wall Street Analyst Weigh In

Several research firms recently commented on DYN. HC Wainwright reiterated a “buy” rating and set a $50.00 price objective on shares of Dyne Therapeutics in a research note on Monday, August 17th. Evercore set a $33.00 price target on shares of Dyne Therapeutics in a report on Friday, May 15th. TD Cowen assumed coverage on shares of Dyne Therapeutics in a report on Friday, June 26th. They issued a “buy” rating on the stock. Morgan Stanley reduced their price target on Dyne Therapeutics from $45.00 to $36.00 and set an “overweight” rating on the stock in a research report on Wednesday. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Dyne Therapeutics in a report on Friday, July 17th. Two analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, one has given a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, Dyne Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $32.17.

Dyne Therapeutics Company Profile

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.